The present invention features solid pharmaceutical compositions comprising Compound 1 (or a pharmaceutically acceptable salt thereof), Compound 2 (or a pharmaceutically acceptable salt thereof), and ritonavir (a pharmaceutically acceptable salt thereof), which are co-formulated in amorphous solid dispersion comprising a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant.本發明特徵為包含化合物1(或其醫藥上可接受的鹽)、化合物2(或其醫藥上可接受的鹽)及利托那韋(ritonavir)(或其醫藥上可接受的鹽)之固態醫藥組合物,其等係共同調配於包含醫藥上可接受的親水性聚合物及醫藥上可接受的表面活性劑之非晶固態分散劑中。
